-
Difloxacin HCl: Mechanism-to-Assay Guide
2026-09-10
Difloxacin HCl connects bacterial DNA replication inhibition with antimicrobial susceptibility testing and multidrug resistance reversal research. This guide adds a mechanistic assay framework informed by Plk1–p31comet checkpoint biology while clearly separating supported evidence from cross-domain interpretation.
-
ROS-Responsive Lipid Nanoparticles for Mutant RAS
2026-09-10
This study develops a combinatorial library of thioketal-containing, ROS-degradable lipids to preferentially deliver mRNA into tumor cells. The lead formulation, BAmP-TK-12, delivered DUF5 mRNA to cleave mutant RAS and produced stronger antitumor activity than a small-molecule RAS inhibitor in the reported models.
-
Camptothecin as a Lens on DNA Damage and Adaptation
2026-09-09
Camptothecin is more than a cytotoxicity reagent: as a topoisomerase I inhibitor, it provides a controlled way to connect DNA damage, cell fate, autophagy, and adaptive evolution. This article outlines a translational workflow that integrates γH2AX and pathway readouts with the emerging biology of reversible mutagenesis states.
-
Human iPSC Intestinal Organoids for Pharmacokinetics
2026-09-09
Saito and colleagues established a direct three-dimensional cluster-culture strategy for generating expandable, cryopreservable intestinal organoids from human induced pluripotent stem cells. The resulting organoids produced intestinal epithelial monolayers containing mature cell types and enterocytes with drug-metabolizing enzyme and transporter activities, creating a more human-relevant platform for oral drug pharmacokinetic research.
-
Cisplatin as a Precision Model of Ovarian Injury
2026-09-08
Cisplatin and CDDP are more than cytotoxicity tools: they can model DNA-damage-driven ovarian granulosa cell injury and reveal cytoprotective signaling. This article connects an exosome-based PTEN/AKT/mTOR study to practical apoptosis assay design and reproducible cancer research workflows.
-
2-Deoxy-D-glucose in Cancer Metabolism Workflows
2026-09-07
2-DG provides a practical way to perturb glycolytic energy supply while connecting ATP loss with tumor-cell viability and immune-resistance assays. This workflow translates the lactate–H3K18la–KIF20A–c-Myc–PD-L1 model into measurable experiments without overstating what the reference study established about 2-DG itself.
-
Fenofibrate, Aging Mice, and PPARα–YAP Signaling
2026-09-07
The reference study shows that Fenofibrate-induced liver enlargement and activation of the PPARα–YAP signaling axis remain broadly comparable in adult and aging mouse models. By combining chemically induced, naturally aged, and senescence-accelerated mice, the work separates age-related regenerative decline from the preserved hepatic response to a PPARα agonist.
-
Fenofibrate: Mapping PPARα–YAP Research Decisions
2026-09-05
Fenofibrate is a PPARα agonist whose effects can be separated into receptor activation, lipid remodeling, YAP signaling, and cell-growth phenotypes. This decision-focused guide translates aging-liver findings into practical assay design, formulation, and interpretation strategies.
-
Fenofibrate, PPARα-YAP Signaling, and Aging Liver
2026-09-05
The reference study shows that Fenofibrate induces comparable liver enlargement and PPARα-YAP pathway activation in adult and aging mice. By combining chemically induced, naturally aged, and senescence-accelerated models, it argues that this hepatic response is largely preserved with age and provides a framework for studying receptor-driven liver remodeling.
-
Carbenoxolone disodium: Practical Lab Guide
2026-09-04
Carbenoxolone disodium is a research tool for probing 11β-hydroxysteroid dehydrogenase activity, corticosterone metabolism, glucocorticoid receptor regulation, and gap junction communication. It is best suited to controlled cell- and tissue-based experiments, not in vivo efficacy studies or assays that require a highly selective single-target probe.
-
Gefitinib (ZD1839) for EGFR Mechanism Studies
2026-09-04
Gefitinib (ZD1839) provides a defined way to test whether EGFR activity controls phosphorylation, proliferation, and apoptosis in cancer and epithelial models. This workflow connects blue-light skin-barrier research with practical pathway validation while preserving clear boundaries between mechanistic evidence and therapeutic interpretation.
-
Ibrutinib (PCI-32765) Workflow for BTK Studies
2026-09-03
Build reproducible B-cell receptor signaling assays with PCI-32765, from solvent handling and anti-IgM stimulation to washout experiments that exploit irreversible BTK inhibition. The workflow also shows how ATRX-aware study design can inform, but not overstate, exploratory kinase-inhibitor research in glioma models.
-
Solanesol B8776: Practical Workflow Guide
2026-09-02
Solanesol B8776 provides a defined polyisoprenoid alcohol for hydrophobic biochemical, membrane-related, cell-based, and enzyme workflows. Its insolubility in water and ethanol requires DMSO-based preparation, fresh-solution handling, and solvent-matched controls; it is intended for research use only, not diagnostic or clinical applications.
-
HyperScribe T7 High Yield RNA Synthesis Kit Plus
2026-09-02
Build high-yield RNA workflows for mRNA rescue, antisense studies, RNAi, and probe design with a streamlined T7 system. The kit combines scalable transcription with support for modified nucleotides, enabling research teams to move from template design to functional RNA testing faster.
-
5X Protein Loading Buffer (Reducing) Guide
2026-09-01
5X Protein Loading Buffer (Reducing) simplifies reducing, denaturing protein sample preparation for conventional SDS-PAGE electrophoresis and protein molecular weight separation. It is not appropriate when native conformation, intact disulfide-linked assemblies, or non-reducing conditions must be preserved.